In MM, aberrant MEK/ERK signaling is known to have an important role in disease progression and prognosis and small molecule inhibitors have shown promise in pre-clinical evaluation.43, 44, 45 Frequent activation of the PI3K/AKT pathway in MM cells has also been observed46, 47 and a number of PI3K inhibitors induce apoptosis in MM cells.48, 49, 50, 51 Moreover, the combination of PI3K inhibition and HDACi has demonstrated synergistic killing in some cancers,52, 53, 54 however, the rational utilization of this combination for MM has not been reported elsewhere. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.